Navigation Links
Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
Date:1/6/2009

AMSTERDAM, January 6 /PRNewswire/ -- Biopharmaceutical Company Kiadis Pharma focused on the development of innovative cell based therapeutics in the field of bone marrow transplantation, announces today the appointment of Dr. Maarten Egeler as Chief Medical Officer (CMO). Dr. Egeler is a global leading pediatric bone marrow transplantation physician and an internationally-recognized authority in pediatric hemato-oncology. He brings to Kiadis Pharma over more than 20 years of expertise in this field.

The appointment of Dr. Egeler is an important milestone in the development of Kiadis Pharma's lead product ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients. Dr. Egeler's appointment will strongly support the upcoming multi-center pivotal study on ATIR(TM) early 2009.

Dr. Egeler will join Kiadis Pharma part time next to his position as Head of the Pediatric Oncology and Bone Marrow Transplantation division of the University of Leiden. As Kiadis Pharma's CMO, he will oversee all medical affairs of the company and he will work closely with the company's global network of key opinion leaders in the transplantation community on the development of the company's products.

"Maarten has been acting as a medical advisor for Kiadis Pharma over the last year and we are very pleased that he agreed to become our CMO", says Manja Bouman, CEO of Kiadis Pharma. "The depth of his medical expertise in the field of bone marrow transplantations, his leadership worldwide in haplo-identical transplantation and his network with key opinion leaders in the field will greatly contribute to the success of our products and company".

"I am very excited to join Kiadis Pharma in the role of CMO. I look forward to participate in the development of its programs. I am particularly excited to work on the ATIR(TM) product, which is aimed at preventing acute Graft versus Host Disease and thus enables severe mismatched bone marrow transplantation (so-called 'haplo-identical transplantation') and is entering a pivotal study in early 2009", says Maarten Egeler. "I am confident that my background in this field within the pediatric setting will be valuable for the company."

    For the complete press release please go to:http://www.kiadis.com/news

    For more information please contact:
    Kiadis Pharma B.V.
    Eefje Simpelaar
    Director Communications
    Email: e.simpelaar@kiadis.com
    Tel: +31-20-3140250
    Mob: +31-6-10829344


'/>"/>
SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
9. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... TORONTO , Nov. 30, 2016 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is excited to announce ... company focused on developing preclinical ophthalmology assets through ... a potent anti-inflammatory created by Portage Pharmaceuticals Limited ... patients with ocular surface and anterior segment diseases. ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  Tempus, ... customized cancer care, and Penn,s Abramson Cancer Center ... have a positive response to immunotherapy treatment based ... As part of a research collaboration, ... pancreatic and melanoma cancer patient data to Penn. ...
(Date:11/30/2016)... 2016   Merck , a leading science and ... a set of agreements with Evotec AG, whereby Evotec ... genetic reagents such as CRISPR and shRNA libraries. Combining ... an accelerated pathway to explore and identify new drug ... of new targets, a process that can be time- ...
(Date:11/30/2016)... ... 2016 , ... On 28 November 2016, the International Union of Pure and ... moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, 115, 117, and ... the discoverers have been approved by the IUPAC Bureau. The IUPAC Council will be ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016   Neurotechnology , ... object recognition technologies, today released FingerCell 3.0, ... recognition solutions that run on low-power, low-memory ... using less than 128KB of memory, enabling ... that have limited on-board resources, such as: ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
Breaking Biology News(10 mins):